ARCT - アルコブラ (Arcturus Therapeutics Ltd.) アルコブラ

 ARCTのチャート


 ARCTの企業情報

symbol ARCT
会社名 Arcturus Therapeutics Ltd (アルコブラ)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Arcturus Therapeutics Ltd formerly Alcobra Ltd is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company through Arcturus Therapeutics Inc its wholly owned subsidiary based in the United States is focused on developing RNA medicines for rare infectious fibrotic and respiratory diseases with unmet medical needs including cystic fibrosis nonalcoholic steatohepatitis (NASH) and rare liver diseases as well as replicon RNA vaccines.   アルコブラはイスラエルの新興バイオ医薬品会社。意欠陥多動性障害(ADHD)治療薬で、特許取得済経口薬のメタドキシン(MDX)や脆弱X症候群などの他の認知機能障害の治療薬の研究、開発、商業化に従事している。MDXは非刺激性の持続放出製剤である。本社はテルアビブ。   
本社所在地 Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel-Aviv 6701101 ISR
代表者氏名 Peter C. Farrell ピーターC.ファレル
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-900-2660
設立年月日 39479
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 60人
url www.alcobra-pharma.com
nasdaq_url https://www.nasdaq.com/symbol/arct
adr_tso
EBITDA EBITDA(百万ドル) -19.10700
終値(lastsale) 7.52
時価総額(marketcap) 80764800
時価総額 時価総額(百万ドル) 79.24800
売上高 売上高(百万ドル) 17.75100
企業価値(EV) 企業価値(EV)(百万ドル) 39.47100
当期純利益 当期純利益(百万ドル) -20.21200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arcturus Therapeutics Ltd revenues decreased 38% to $4.8M. Net loss increased from $2.4M to $16.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative increase from $2.1M to $13.3M (expense) Research and development increase of 2% to $8.2M (expense).

 ARCTのテクニカル分析


 ARCTのニュース

   B.Riley Financial Stick to Their Sell Rating for Arcturus Therapeutics By Investing.com  2021/03/05 19:25:01 Investing.com
B.Riley Financial Stick to Their Sell Rating for Arcturus Therapeutics
   Arcturus Therapeutics Must-See Earnings Estimates for: Stock market Insights & financial analysis  2021/03/01 16:05:00 Stock Market Daily
Arcturus Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Arcturus Therapeutics : Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals | MarketScreener  2021/02/22 13:06:02 MarketScreener
Arcturus Therapeutics Holdings Inc. , a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and… | February 22, 2021
   Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals  2021/02/22 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
   Arcturus Therapeutics, Chesapeake Energy, Square, and More Wednesday Afternoon Analyst Calls  2021/02/17 19:20:55 24/7 Wall street
   B.Riley Financial Stick to Their Sell Rating for Arcturus Therapeutics By Investing.com  2021/03/05 19:25:01 Investing.com
B.Riley Financial Stick to Their Sell Rating for Arcturus Therapeutics
   Arcturus Therapeutics Must-See Earnings Estimates for: Stock market Insights & financial analysis  2021/03/01 16:05:00 Stock Market Daily
Arcturus Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Arcturus Therapeutics : Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals | MarketScreener  2021/02/22 13:06:02 MarketScreener
Arcturus Therapeutics Holdings Inc. , a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and… | February 22, 2021
   Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals  2021/02/22 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
   Arcturus Therapeutics, Chesapeake Energy, Square, and More Wednesday Afternoon Analyst Calls  2021/02/17 19:20:55 24/7 Wall street
   B.Riley Financial Stick to Their Sell Rating for Arcturus Therapeutics By Investing.com  2021/03/05 19:25:01 Investing.com
B.Riley Financial Stick to Their Sell Rating for Arcturus Therapeutics
   Arcturus Therapeutics Must-See Earnings Estimates for: Stock market Insights & financial analysis  2021/03/01 16:05:00 Stock Market Daily
Arcturus Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Arcturus Therapeutics : Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals | MarketScreener  2021/02/22 13:06:02 MarketScreener
Arcturus Therapeutics Holdings Inc. , a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and… | February 22, 2021
   Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals  2021/02/22 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
   Arcturus Therapeutics, Chesapeake Energy, Square, and More Wednesday Afternoon Analyst Calls  2021/02/17 19:20:55 24/7 Wall street

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルコブラ ARCT Arcturus Therapeutics Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)